$REGN
Regeneron Pharmaceuticals Inc

2012 Q3 Form 10-Q Financial Statement

#000153217612000004 Filed on October 24, 2012

View on sec.gov

Income Statement

Concept 2012 Q3 2011 Q4 2011 Q3
Revenue $427.7M $123.0M $102.8M
YoY Change 315.9% -8.02% -2.99%
Cost Of Revenue $20.15M $3.000M $450.0K
YoY Change 4376.67% 400.0% 12.5%
Gross Profit $407.5M $120.0M $102.4M
YoY Change 298.06% -9.84% -3.05%
Gross Profit Margin 95.29% 97.58% 99.56%
Selling, General & Admin $46.88M $36.30M $32.92M
YoY Change 42.43% 76.21% 109.66%
% of Gross Profit 11.5% 30.25% 32.15%
Research & Development $158.3M $129.0M $127.9M
YoY Change 23.74% 3.04% 4.86%
% of Gross Profit 38.84% 107.5% 124.95%
Depreciation & Amortization $9.400M $7.900M $8.300M
YoY Change 13.25% 29.51% 69.39%
% of Gross Profit 2.31% 6.58% 8.11%
Operating Expenses $205.2M $165.4M $160.8M
YoY Change 27.57% 13.37% 16.8%
Operating Profit $202.4M -$45.40M -$58.46M
YoY Change -446.18% 254.69% 82.11%
Interest Expense $11.41M -$9.500M $4.061M
YoY Change 181.04% 280.0% -284.59%
% of Operating Profit 5.64%
Other Income/Expense, Net -$10.90M $800.0K -$3.346M
YoY Change 225.64% 33.33% -769.2%
Pretax Income $191.5M -$54.10M -$61.80M
YoY Change -409.8% 270.55% 82.31%
Income Tax -$600.0K $562.0K
% Of Pretax Income
Net Earnings $191.5M -$53.44M -$62.37M
YoY Change -407.01% 266.05% 83.97%
Net Earnings / Revenue 44.77% -43.46% -60.65%
Basic Earnings Per Share $2.02 -$0.68
Diluted Earnings Per Share $1.72 -$581.7K -$0.68
COMMON SHARES
Basic Shares Outstanding 95.01M shares 91.05M shares
Diluted Shares Outstanding 115.8M shares 91.05M shares

Balance Sheet

Concept 2012 Q3 2011 Q4 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $263.0M $527.0M $245.0M
YoY Change 7.35% 111.65% -48.85%
Cash & Equivalents $119.0M $483.6M $206.4M
Short-Term Investments $144.0M $43.00M $39.00M
Other Short-Term Assets $55.00M $36.00M $16.00M
YoY Change 243.75% 38.46% 14.29%
Inventory $29.57M $16.61M
Prepaid Expenses
Receivables $506.7M $28.25M $75.00M
Other Receivables $0.00 $0.00 $3.000M
Total Short-Term Assets $948.6M $665.8M $340.0M
YoY Change 179.0% 85.97% -40.97%
LONG-TERM ASSETS
Property, Plant & Equipment $372.9M $368.0M $364.0M
YoY Change 2.45% 5.9% 14.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $313.0M $276.0M $258.0M
YoY Change 21.32% -25.41% 578.95%
Other Assets $18.32M $6.243M $21.00M
YoY Change -12.75% -55.41% 110.0%
Total Long-Term Assets $712.0M $657.8M $643.0M
YoY Change 10.73% -10.01% 75.68%
TOTAL ASSETS
Total Short-Term Assets $948.6M $665.8M $340.0M
Total Long-Term Assets $712.0M $657.8M $643.0M
Total Assets $1.661B $1.324B $983.0M
YoY Change 68.93% 21.54% 4.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $22.00M $28.00M $21.00M
YoY Change 4.76% 55.56% -8.7%
Accrued Expenses $102.0M $68.00M $58.00M
YoY Change 75.86% 88.89% 11.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $178.6M $148.3M $133.0M
YoY Change 34.26% 36.03% -0.75%
LONG-TERM LIABILITIES
Long-Term Debt $450.0M $435.0M $159.0M
YoY Change 183.02% 173.58% 0.63%
Other Long-Term Liabilities $6.987M $6.443M $262.0M
YoY Change -97.33% -97.8% -13.25%
Total Long-Term Liabilities $6.987M $6.443M $421.0M
YoY Change -98.34% -98.57% -8.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $178.6M $148.3M $133.0M
Total Long-Term Liabilities $6.987M $6.443M $421.0M
Total Liabilities $854.6M $837.9M $555.0M
YoY Change 53.98% 49.08% -6.57%
SHAREHOLDERS EQUITY
Retained Earnings -$987.5M -$1.267B
YoY Change
Common Stock $94.00K $91.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $806.0M $485.7M $428.3M
YoY Change
Total Liabilities & Shareholders Equity $1.661B $1.324B $983.0M
YoY Change 68.93% 21.54% 4.35%

Cashflow Statement

Concept 2012 Q3 2011 Q4 2011 Q3
OPERATING ACTIVITIES
Net Income $191.5M -$53.44M -$62.37M
YoY Change -407.01% 266.05% 83.97%
Depreciation, Depletion And Amortization $9.400M $7.900M $8.300M
YoY Change 13.25% 29.51% 69.39%
Cash From Operating Activities -$2.400M -$50.30M -$46.80M
YoY Change -94.87% 22.98% -128.98%
INVESTING ACTIVITIES
Capital Expenditures -$10.30M -$11.30M -$8.900M
YoY Change 15.73% -65.02% -59.73%
Acquisitions
YoY Change
Other Investing Activities -$38.50M -$22.60M $8.000M
YoY Change -581.25% -92.99% -88.93%
Cash From Investing Activities -$48.80M -$33.90M -$900.0K
YoY Change 5322.22% -90.44% -101.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.800M 361.4M -300.0K
YoY Change 500.0% 97.7% -118.75%
NET CHANGE
Cash From Operating Activities -2.400M -50.30M -46.80M
Cash From Investing Activities -48.80M -33.90M -900.0K
Cash From Financing Activities -1.800M 361.4M -300.0K
Net Change In Cash -53.00M 277.2M -48.00M
YoY Change 10.42% -230.32% -122.5%
FREE CASH FLOW
Cash From Operating Activities -$2.400M -$50.30M -$46.80M
Capital Expenditures -$10.30M -$11.30M -$8.900M
Free Cash Flow $7.900M -$39.00M -$37.90M
YoY Change -120.84% 353.49% -120.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
124224000 USD
CY2011Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
95625000 USD
CY2012Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
21943000 USD
CY2011Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
27736000 USD
CY2012Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
506682000 USD
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28254000 USD
CY2011Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
700000 USD
CY2012Q3 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
1700000 USD
CY2011Q3 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
1100000 USD
CY2010Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
1400000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1862000 USD
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1904000 USD
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1754824000 USD
CY2012Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1795293000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
16316000 USD
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
71475000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40768000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
63507000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-447662000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
76952000 USD
CY2012Q3 us-gaap Assets
Assets
1660615000 USD
CY2011Q4 us-gaap Assets
Assets
1323583000 USD
CY2012Q3 us-gaap Assets Current
AssetsCurrent
948603000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
665777000 USD
CY2012Q3 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
460911000 USD
CY2011Q4 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
321845000 USD
CY2012Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
461639000 USD
CY2011Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
322138000 USD
CY2012Q3 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
84000 USD
CY2011Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
236000 USD
CY2011Q3 us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
600000 USD
us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
-500000 USD
CY2012Q3 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
812000 USD
CY2011Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
529000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
483610000 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118998000 USD
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
206395000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112572000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-364612000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
93823000 USD
CY2012Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000 shares
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000 shares
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
94410423 shares
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
90692071 shares
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
94410423 shares
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
90692071 shares
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
94000 USD
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
91000 USD
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
191935000 USD
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63192000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
279820000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-167557000 USD
us-gaap Contracts Revenue
ContractsRevenue
2231000 USD
us-gaap Contracts Revenue
ContractsRevenue
5672000 USD
CY2012Q3 us-gaap Contracts Revenue
ContractsRevenue
879000 USD
CY2011Q3 us-gaap Contracts Revenue
ContractsRevenue
1576000 USD
CY2012Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
763900000 USD
CY2011Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
275019000 USD
CY2012Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
290959000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
54286000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
1227000 USD
CY2011Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
450000 USD
CY2012Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
20145000 USD
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
225323000 USD
CY2011Q3 us-gaap Costs And Expenses
CostsAndExpenses
161290000 USD
us-gaap Costs And Expenses
CostsAndExpenses
482604000 USD
us-gaap Costs And Expenses
CostsAndExpenses
651832000 USD
CY2012Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
400000000 USD
CY2012Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.01875
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33479000 USD
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
31629000 USD
CY2012Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
141132000 USD
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
162593000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27162000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
23156000 USD
CY2012Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
94589000 USD
CY2011Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
74781000 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.97
CY2011Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.87
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.02
CY2011Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.87
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.55
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
42835000 USD
CY2012Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
46620000 USD
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
2700000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
279862000 USD
CY2011Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-61803000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-168834000 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
191468000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-517000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2011Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
562000 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
35254000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
29231000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4933000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
498236000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-32498000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-28605000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
61892000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3425000 USD
us-gaap Increase Decrease In Restricted Cash And Investments
IncreaseDecreaseInRestrictedCashAndInvestments
518000 USD
us-gaap Increase Decrease In Restricted Cash And Investments
IncreaseDecreaseInRestrictedCashAndInvestments
685000 USD
CY2012Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1154000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
652000 shares
CY2011Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
shares
CY2011Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
shares
CY2012Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
4761000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
CY2011Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
CY2012Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14106000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14080000 shares
us-gaap Interest Expense
InterestExpense
11827000 USD
us-gaap Interest Expense
InterestExpense
33809000 USD
CY2012Q3 us-gaap Interest Expense
InterestExpense
11413000 USD
CY2011Q3 us-gaap Interest Expense
InterestExpense
4061000 USD
CY2012Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
7374000 USD
CY2011Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
USD
CY2012Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4437000 USD
CY2011Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1142000 USD
CY2012Q3 us-gaap Inventory Net
InventoryNet
29570000 USD
CY2011Q4 us-gaap Inventory Net
InventoryNet
16614000 USD
CY2011Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4666000 USD
CY2012Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
6553000 USD
CY2011Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
10806000 USD
CY2012Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
18580000 USD
CY2012Q3 us-gaap Inventory Write Down
InventoryWriteDown
200000 USD
us-gaap Inventory Write Down
InventoryWriteDown
8600000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2750000 USD
CY2012Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
517000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1628000 USD
CY2011Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
715000 USD
CY2011Q4 us-gaap Liabilities
Liabilities
837851000 USD
CY2012Q3 us-gaap Liabilities
Liabilities
854591000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1323583000 USD
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1660615000 USD
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
178568000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
148271000 USD
CY2011Q3 us-gaap Licenses Revenue
LicensesRevenue
5893000 USD
CY2012Q3 us-gaap Licenses Revenue
LicensesRevenue
5893000 USD
us-gaap Licenses Revenue
LicensesRevenue
17679000 USD
us-gaap Licenses Revenue
LicensesRevenue
18966000 USD
CY2011Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
43332000 USD
CY2012Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
143554000 USD
CY2012Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
312600000 USD
CY2011Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
275887000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22809000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-24636000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
162379000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-172176000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91365000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-167800000 USD
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-62365000 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
191468000 USD
us-gaap Net Income Loss
NetIncomeLoss
279862000 USD
us-gaap Net Income Loss
NetIncomeLoss
-168317000 USD
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
198842000 USD
CY2011Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-62365000 USD
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10896000 USD
CY2011Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3346000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32181000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9077000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-159757000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
312043000 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
202364000 USD
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-58457000 USD
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11257000 USD
CY2012Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
22198000 USD
CY2012Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18322000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6243000 USD
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
467000 USD
CY2011Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-827000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-42000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
760000 USD
CY2012Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6987000 USD
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6443000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-21293000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2121000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
16316000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
71475000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
398253000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
115538000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
34175000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
45928000 USD
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
35800000 USD
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
84780000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48440000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40135000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
260770000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
324530000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
367955000 USD
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
372917000 USD
us-gaap Related Party Transaction Revenues From Transactions With Related Party
RelatedPartyTransactionRevenuesFromTransactionsWithRelatedParty
319035000 USD
CY2011Q3 us-gaap Related Party Transaction Revenues From Transactions With Related Party
RelatedPartyTransactionRevenuesFromTransactionsWithRelatedParty
79802000 USD
us-gaap Related Party Transaction Revenues From Transactions With Related Party
RelatedPartyTransactionRevenuesFromTransactionsWithRelatedParty
249577000 USD
CY2012Q3 us-gaap Related Party Transaction Revenues From Transactions With Related Party
RelatedPartyTransactionRevenuesFromTransactionsWithRelatedParty
145042000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1601000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1010000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
400465000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
444530000 USD
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
127924000 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
158295000 USD
CY2011Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
7721000 USD
CY2012Q3 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
8173000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1267323000 USD
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-987461000 USD
us-gaap Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">Revenue from product sales are recorded net of applicable provisions for prompt pay discounts, rebates and chargebacks under governmental programs (including Medicaid), product returns, distribution-related fees, and other sales-related deductions. </font></div></div>
us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">The Company records revenue from product sales upon delivery to its customers.</font></div></div>
CY2012Q3 us-gaap Revenues
Revenues
427687000 USD
us-gaap Revenues
Revenues
322847000 USD
us-gaap Revenues
Revenues
963875000 USD
CY2011Q3 us-gaap Revenues
Revenues
102833000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
14934000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
576622000 USD
CY2011Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
5468000 USD
CY2012Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
249172000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
153016000 USD
CY2011Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
32916000 USD
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46883000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
80912000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
40561000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
63385000 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
USD
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
3405000 USD
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
USD
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
40138000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48440000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
485732000 USD
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
806024000 USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
527815000 USD
CY2011Q3 us-gaap Stockholders Equity
StockholdersEquity
428253000 USD
CY2012Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
21464000 USD
CY2011Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
2218000 USD
us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
44471000 USD
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
25225000 USD
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15431000 shares
CY2011Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2012Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
20818000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2011Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91046000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90215000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109780000 shares
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115830000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90215000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94349000 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95012000 shares
CY2011Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91046000 shares
CY2012Q3 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
7000000 USD
CY2011Q3 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
4900000 USD
CY2011Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
6200000 USD
CY2010Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
10700000 USD
CY2011Q4 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
9850000 USD
CY2012Q3 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
11502000 USD
CY2011Q4 regn Accrued Sales Related Deductions And Royalties
AccruedSalesRelatedDeductionsAndRoyalties
3947000 USD
CY2012Q3 regn Accrued Sales Related Deductions And Royalties
AccruedSalesRelatedDeductionsAndRoyalties
21961000 USD
CY2012Q3 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
19588000 USD
CY2011Q4 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
20011000 USD
CY2011Q4 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
86017000 USD
CY2012Q3 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
77446000 USD
CY2012Q3 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
1277000 USD
CY2011Q4 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
1006000 USD
CY2012Q3 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
159499000 USD
CY2011Q4 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
159508000 USD
CY2011Q3 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
699000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
shares
CY2012Q3 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
797000 shares
regn Other Collaboration Revenue
OtherCollaborationRevenue
33698000 USD
CY2012Q3 regn Other Collaboration Revenue
OtherCollaborationRevenue
26701000 USD
CY2011Q3 regn Other Collaboration Revenue
OtherCollaborationRevenue
10094000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
48308000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000872589
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2011Q2 dei Entity Public Float
EntityPublicFloat
4913223000 USD
dei Entity Registrant Name
EntityRegistrantName
REGENERON PHARMACEUTICALS INC
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes

Files In Submission

Name View Source Status
0001532176-12-000004-index-headers.html Edgar Link pending
0001532176-12-000004-index.html Edgar Link pending
0001532176-12-000004.txt Edgar Link pending
0001532176-12-000004-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regn-20120930.xml Edgar Link completed
regn-20120930.xsd Edgar Link pending
regn-20120930_cal.xml Edgar Link unprocessable
regn-20120930_def.xml Edgar Link unprocessable
regn-20120930_lab.xml Edgar Link unprocessable
regn-20120930_pre.xml Edgar Link unprocessable
regn-93012x10q.htm Edgar Link pending
regn-ex_311x9302012x10q.htm Edgar Link pending
regn-ex_312x9302012x10q.htm Edgar Link pending
regn-ex_32x9302012x10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending